PD-L1 TPS ≥ 50% was selected as the IHC 22C3 companion diagnostic cutoff from among highly similar results for four scoring methods because it was the simplest approach to implement in clinical practice, with the investigators concluding PD-L1 expression in NSCLC is tumor-specific [16,17]. The gene discussed is CD274; the disease is neoplasm.